证券日报网讯 2月13日，太极集团在互动平台回答投资者提问时表示，公司聚焦"一个数字化太极"核心 目标，纵深推进"业务数字化、数据融通化、流程智能化、生态平台化"四化融合工程，全面覆盖营销、 生产、科研等关键领域，赋能全业务流程数字化升级。目前，数据治理与AI建设已实现核心数据入湖 及可视化平台优化，并成功落地AI智能体等创新应用。现代中药产业大脑以数据为引擎，创新构建全 产业链数字化模式，引领中药产业向智能化、标准化全面转型。 （文章来源：证券日报） ...

重庆太极实业（集团）股份有限公司 2026 年第一次临时股东会会议资料 重庆太极实业（集团）股份有限公司 2026 年第一次临时股东会资料 2026 年 2 月 重庆太极实业（集团）股份有限公司 2026 年第一次临时股东会会议资料 目录 一、关于预计公司2026年度日常关联交易额度的议案.................3 二、关于公司实际控制人延期履行同业竞争承诺的议案.....7 1 重庆太极实业（集团）股份有限公司 2026 年第一次临时股东会会议资料 重庆太极实业（集团）股份有限公司 2026 年第一次临时股东会议程 重庆太极实业（集团）股份有限公司 2026 年 2 月 27 日 2 一、主持人宣布会议开始； 二、主持人报告股东现场到会情况； 三、到会股东审议如下议案： 1.关于预计公司 2026 年度日常关联交易额度的议案； 2.关于公司实际控制人延期履行同业竞争承诺的议案。 四、会议讨论； 五、股东及其委托代理人对相关议案投票表决； 六、表决统计； 七、见证律师宣读法律意见书； 八、到会董事在会议决议上签字； 九、主持人宣布会议结束。 重庆太极实业（集团）股份有限公司 2026 年第一次临时股 ...

Group 1 - The core point of the article is that Taiji Group (600129) announced a plan to optimize its equity structure by acquiring a 90% stake in Tongjun Pavilion Chinese Medicine Wholesale for 21.08 million yuan and a 10% stake for 2.35 million yuan from its subsidiaries [1] - The share transfer is between the company and its controlling subsidiaries, meaning it does not involve external shareholders [1] - The announcement states that the share transfer will not change the scope of the company's consolidated financial statements and will not adversely affect the company's financial and operational status [1]

Investment Rating - The report maintains a "Buy" rating for key companies in the pharmaceutical sector, including Innovent Biologics, Efang Biologics, Tianshili, WuXi AppTec, and Mindray Medical [4][28]. Core Insights - The policy-driven upgrade of traditional Chinese medicine (TCM) industry is expected to enhance industry concentration in the medium to long term, benefiting companies with strong quality control and innovative capabilities [2][24]. - The implementation plan for high-quality development of the TCM industry aims to establish a collaborative development system by 2030, focusing on raw material supply, innovation, production quality control, and internationalization [2][23]. - The investment strategy emphasizes the importance of clinical value in the pharmaceutical sector, recommending a focus on innovative drugs and high-end medical devices [3][26]. Summary by Sections Market Review - The A-share pharmaceutical index rose by 0.14%, outperforming the CSI 300 index by 1.47 percentage points [1][16]. - The Hong Kong Hang Seng Medical Health Index fell by 1.41%, but still outperformed the Hang Seng Index by 1.65 percentage points [1][16]. Policy Insights - The Ministry of Industry and Information Technology and other departments issued a plan to enhance the TCM industry, which includes fostering leading enterprises and establishing high-standard raw material production bases [2][24]. - The plan emphasizes digitalization and sustainability, aiming to raise compliance standards and accelerate the exit of smaller companies from the market [2][25]. Company Updates - Recent clinical progress includes the NDA submission for HRS-9531 by Heng Rui Medicine and the initiation of clinical trials for various drugs by other companies [1][31][32]. - Key companies such as Yunnan Baiyao, Baiyunshan, and Taiji Group are highlighted for their strong positions in raw material supply [2][25]. Financial Forecasts - The report provides earnings per share (EPS) forecasts for key companies, with Innovent Biologics projected to have an EPS of 0.49 in 2025 and WuXi AppTec expected to reach an EPS of 5.07 in the same year [4][28]. - The pharmaceutical manufacturing industry reported a revenue decline of 1.2% year-on-year for 2025, with total revenue reaching 2,487 billion yuan [51].

Group 1 - The company, Chongqing Taiji Industrial (Group) Co., Ltd., plans to acquire 100% equity of Chongqing Tongjun Pavilion Traditional Chinese Medicine Wholesale Co., Ltd. by purchasing 90% from Chongqing Chinese Medicinal Materials Co., Ltd. for 21.08 million yuan and 10% from Taiji Group Chongqing Fuling Pharmaceutical Co., Ltd. for 2.35 million yuan [2][3][14] - The equity transfer has been approved by the company's board of directors and does not require shareholder approval as it falls within the board's authority [4][15] - The transaction does not constitute a related party transaction or a major asset restructuring as per the relevant regulations [4][15] Group 2 - Chongqing Tongjun Pavilion Traditional Chinese Medicine Wholesale Co., Ltd. has total assets of 77 million yuan, net assets of 23.42 million yuan, operating income of 136.03 million yuan, and net profit of 2.91 million yuan as of December 31, 2024 [6] - Chongqing Chinese Medicinal Materials Co., Ltd. has total assets of 358.31 million yuan, net assets of 55.29 million yuan, and operating income of 409.18 million yuan, but reported a net loss of 18.19 million yuan as of December 31, 2024 [7] - Taiji Group Chongqing Fuling Pharmaceutical Co., Ltd. has total assets of 231.27 million yuan, net assets of 58.46 million yuan, and operating income of 315.24 million yuan, with a net profit of 2.05 million yuan as of December 31, 2024 [9] Group 3 - The acquisition aims to optimize the company's equity structure and consolidate internal resources, ensuring that the company holds 100% of Chongqing Tongjun Pavilion after the transfer [3][15] - The financial impact of the equity transfer is neutral, as it does not change the consolidation scope or adversely affect the company's financial and operational status [15] - The company will enhance management and control over the subsidiary's operations post-acquisition [16]

Core Viewpoint - The company, Taiji Group, is acquiring 100% ownership of Tongjun Pavilion Traditional Chinese Medicine Wholesale Co., Ltd. through the purchase of 90% and 10% stakes from two entities for a total of 23.43 million yuan, aiming to optimize its equity structure and internal resource integration [1] Group 1: Acquisition Details - Taiji Group will acquire 90% of the shares from Chongqing Chinese Herbal Medicine Co., Ltd. for 21.08 million yuan and 10% from Taiji Group Chongqing Fuling Pharmaceutical Co., Ltd. for 2.35 million yuan, totaling 23.43 million yuan [1] - After the completion of the share transfer, Taiji Group will hold 100% of the shares in Tongjun Pavilion Traditional Chinese Medicine Wholesale, with no remaining stakes held by the other two companies [1] Group 2: Strategic Intent - The share transfer is intended to integrate internal resources and optimize the equity structure of the company [1] - The share transfer will not affect the consolidated financial statements or the operational status of the company, as it does not involve external shareholders [1]

Group 1 - The company, Taiji Group, announced that its 10th Board of Directors held its 36th meeting on February 6, 2026, via in-person and video conference [1] - The meeting reviewed the proposal regarding the acquisition of 100% equity of Chongqing Tongjun Pavilion Traditional Chinese Medicine Wholesale Co., Ltd. [1] Group 2 - A central bank, which has been increasing its gold reserves for two consecutive years, announced plans to purchase an additional 150 tons of gold, aiming to stockpile a total of 700 tons [1]

格隆汇2月6日丨太极集团(600129.SH)公布，为了整合内部资源，优化股权结构：1.公司拟以现金2,108 万元的价格受让全资子公司重庆中药材公司持有的桐君阁中药批发90%股权；2.公司拟以现金235万元 的价格受让间接控股子公司涪陵医药持有的桐君阁中药批发10%股权。转让完成后，公司持有桐君阁中 药批发100%股权，重庆中药材公司和涪陵医药不再持有桐君阁中药批发的股权。 ...

2021 年 4 月，该交易完成，国药集团成为太极集团实际控制人。 2025 年 2 月，国药中药向国药集团无偿划转其持有的太极集团控股 股东太极集团有限公司 66.6666%股权。本次无偿划转完成后，国药 中药不再持有太极集团有限公司股权，国药集团仍为太极集团实际控 制人。 证券代码：600129 证券简称：太极集团 公告编号：2026-007 重庆太极实业（集团）股份有限公司 关于公司实际控制人延期履行同业竞争 承诺的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称"公司"或"太 极集团"）近日收到实际控制人中国医药集团有限公司（以下简称"国 药集团"）出具的《关于同业竞争承诺相关事宜的函》，根据《上市 公司监管指引第4号—上市公司及其相关方承诺》，结合实际情况， 国药集团拟将2020年10月30日出具的《关于避免同业竞争的承诺函》 中相关承诺的履行期限延长五年，除履行承诺期限变更外，其他承诺 内容保持不变。具体如下： 一、原承诺背景及内容 2020 年 10 月，国药集团 ...

证券代码：600129 证券简称：太极集团 公告编号：2026-006 重庆太极实业（集团）股份有限公司 关于受让下属子公司股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重要内容提示： ●重庆太极实业（集团）股份有限公司（以下简称"公司"或"太 极集团"）拟分别受让重庆中药材有限公司（以下简称：重庆中药材 公司）持有重庆桐君阁中药批发有限责任公司（以下简称：桐君阁中 药批发）90%的股权以及太极集团重庆涪陵医药有限公司（以下简称： 涪陵医药）持有桐君阁中药批发10%股权。 ●本次股权转让均为公司与控股子公司之间进行，不涉及外部股 东，不会导致公司合并报表范围发生变化，不会对公司财务及经营状 况产生不利影响。 ●本次桐君阁中药批发股权转让事宜已经公司第十届董事会第 三十六次会议审议通过。根据《公司章程》规定，该事项无需提交公 司股东会审议。 ●本次股权转让事宜不构成《上海证券交易所股票上市规则》和 《公司章程》规定的关联交易，也不构成《上市公司重大资产重组管 理办法》规定的重大资产重组情形。 一、本次股权转让事宜 ...